Patents by Inventor Nikolaj Havnsøe Torp Petersen

Nikolaj Havnsøe Torp Petersen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ARIMOCLOMOL FOR THE TREATMENT OF NIEMANN PICK DISEASE, TYPE C, IN PATIENTS WITH ER TYPE MISSENSE MUTATIONS
    Publication number: 20240115558
    Abstract: The present invention relates to an active pharmaceutical ingredient selected from N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride, its stereoisomers and the acid addition salts thereof; specifically arimoclomol, for use in improved methods of treating Niemann Pick disease, type C (NPC), wherein the patient 5 has an endoplasmic reticulum (ER) type missense mutation in an NPC gene.
    Type: Application
    Filed: December 23, 2021
    Publication date: April 11, 2024
    Inventors: Thomas Kirkegaard Jensen, Christine l Dali, Nikolaj Havnsøe Torp Petersen, Thomas Blaettler, Lærke Clement Freiberg
  • USE OF ARIMOCLOMOL IN THE TREATMENT OF NIEMANN PICK DISEASE
    Publication number: 20220211687
    Abstract: This application is directed to assays, diagnostic methods and treatment methods using arimoclomol for the treatment of Niemann-Pick disease type C (NPC). More specifically, this application is directed to assays, diagnostics methods and treatment methods that target specific clinical subsets of patients with NPC who exhibit at least one missense mutation in at least one allele of an NPC gene.
    Type: Application
    Filed: December 23, 2021
    Publication date: July 7, 2022
    Inventors: Thomas Kirkegaard JENSEN, Christine í. DALI, Nikolaj Havnsøe Torp PETERSEN, Thomas BLAETTLER, Lærke Clement FREIBERG
  • ARIMOCLOMOL FOR TREATING GLUCOCEREBROSIDASE ASSOCIATED DISORDERS
    Publication number: 20220133707
    Abstract: The present invention relates to an active pharmaceutical ingredient selected from N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride, its stereoisomers and the acid addition salts thereof (arimoclomol), for use in a method of treating glucocerebrosidase associated disorders.
    Type: Application
    Filed: January 12, 2022
    Publication date: May 5, 2022
    Inventors: Anders Mørkeberg HINSBY, Thomas Kirkegaard JENSEN, Catherine Kolster FOG-TONNESEN, Nikolaj Havnsøe Torp PETERSEN, Claus BORNÆS
  • Arimoclomol for treating glucocerebrosidase associated disorders
    Patent number: 11253505
    Abstract: The present invention relates to an active pharmaceutical ingredient selected from N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride, its stereoisomers and the acid addition salts thereof (arimoclomol), for use in a method of treating glucocerebrosidase associated disorders.
    Type: Grant
    Filed: May 20, 2020
    Date of Patent: February 22, 2022
    Assignee: Orphazyme A/S
    Inventors: Anders Mørkeberg Hinsby, Thomas Kirkegaard Jensen, Catherine Kolster Fog-Tonnesen, Nikolaj Havnsøe Torp Petersen, Claus Bornæs
  • ARIMOCLOMOL FOR TREATING GLUCOCEREBROSIDASE ASSOCIATED DISORDERS
    Publication number: 20200289497
    Abstract: The present invention relates to an active pharmaceutical ingredient selected from N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride, its stereoisomers and the acid addition salts thereof (arimoclomol), for use in a method of treating glucocerebrosidase associated disorders.
    Type: Application
    Filed: May 20, 2020
    Publication date: September 17, 2020
    Inventors: Anders Mørkeberg Hinsby, Thomas Kirkegaard Jensen, Catherine Kolster Fog-Tonnesen, Nikolaj Havnsøe Torp Petersen, Claus Bornæs
  • ARIMOCLOMOL FOR TREATING GLUCOCEREBROSIDASE ASSOCIATED DISORDERS
    Publication number: 20190111041
    Abstract: The present invention relates to an active pharmaceutical ingredient selected from N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximioyl chloride, its stereoisomers and the acid addition salts thereof (arimoclomol), for use in a method of treating glucocerebrosidase associated disorders.
    Type: Application
    Filed: April 28, 2017
    Publication date: April 18, 2019
    Inventors: Anders Mørkeberg Hinsby, Thomas Kirkegaard Jensen, Catherine Kolster Fog-Tonnesen, Nikolaj Havnsøe Torp Petersen, Claus Bornæs